Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Machiko, Umemura"'
Autor:
Machiko Umemura, Goki Suda, Shihori Tsukamoto, Ko Ebata, Shinjiro Takahash, Takashi Sasaki, Sae Nakajima, Koji Hirata, Mariko Ozasa, Masatoshi Takano, Masaki Katagiri, Naoya Sakamoto
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-5 (2021)
Abstract Background In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP
Externí odkaz:
https://doaj.org/article/3c7d88ca3370418b888dcfb69a1a62ee
Autor:
Taku Shigesawa, Goki Suda, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Ren Yamada, Takashi Kitagataya, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Naoya Sakamoto
Publikováno v:
JGH Open, Vol 4, Iss 5, Pp 880-888 (2020)
Abstract Background Sorafenib and lenvatinib are first‐line systemic therapies for unresectable hepatocellular carcinoma (HCC). However, the criteria for their selection remain unclear. Methods We identified patients with unresectable HCC who were
Externí odkaz:
https://doaj.org/article/44b12a677d304da6b40e86a4494f1b3a
Autor:
Takuya Sho, Goki Suda, Koji Ogawa, Megumi Kimura, Tomoe Shimazaki, Osamu Maehara, Taku Shigesawa, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Machiko Umemura, Naoki Kawagishi, Mitsuteru Natsuizaka, Masato Nakai, Kenichi Morikawa, Ken Furuya, Masaru Baba, Yoshiya Yamamoto, Tomoe Kobayashi, Takashi Meguro, Akiyoshi Saga, Takuto Miyagishima, Hideki Yokoo, Toshiya Kamiyama, Akinobu Taketomi, Naoya Sakamoto
Publikováno v:
JGH Open, Vol 4, Iss 1, Pp 54-60 (2020)
Background and Aim Lenvatinib has been recently approved as a first‐line systematic therapy for patients with advanced hepatocellular carcinoma (HCC) based on the results of the phase 3 clinical trial REFLECT. This trial excluded patients with a hi
Externí odkaz:
https://doaj.org/article/ad9240c41307424a80f80afc9c2396ee
Autor:
Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi, Naoya Sakamoto
Publikováno v:
Hepatology Communications, Vol 2, Iss 8, Pp 910-922 (2018)
Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited. In this retrospective study,
Externí odkaz:
https://doaj.org/article/1910db790a9744fbba7e24df81fb4632
Autor:
Naoki Kawagishi, Goki Suda, Akinobu Nakamura, Megumi Kimura, Osamu Maehara, Kazuharu Suzuki, Akihisa Nakamura, Masatsugu Ohara, Takaaki Izumi, Machiko Umemura, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Koji Ogawa, Yusuke Kudo, Mutsumi Nishida, Hideaki Miyoshi, Naoya Sakamoto
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0209615 (2018)
AIM:We comprehensively analyzed how hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting-antiviral-agents (DAAs) affects liver steatosis and atherogenic risk. METHODS:Patients treated with IFN-free-DAAs who underwent transient e
Externí odkaz:
https://doaj.org/article/183f198e79584153bc811e194129dbbf
Autor:
Akihisa Nakamura, Naoya Sakamoto, Takuya Sho, Osamu Maehara, Kenichi Morikawa, Masatsugu Ohara, Machiko Umemura, Kazuharu Suzuki, Goki Suda, Koji Ogawa, Naoki Kawagishi, Mitsuteru Natsuizaka, Takashi Kitagataya, Megumi Kimura, Masato Nakai, Taku Shigesawa, Tomoe Shimazaki, Ren Yamada
Publikováno v:
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
JGH Open, Vol 4, Iss 5, Pp 880-888 (2020)
JGH Open, Vol 4, Iss 5, Pp 880-888 (2020)
Background Sorafenib and lenvatinib are first‐line systemic therapies for unresectable hepatocellular carcinoma (HCC). However, the criteria for their selection remain unclear. Methods We identified patients with unresectable HCC who were treated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cc5833aed4d5942be03c969b33babfb
http://hdl.handle.net/2115/79632
http://hdl.handle.net/2115/79632
Autor:
Kazuharu Suzuki, Takuya Sho, Masatsugu Ohara, Goki Suda, Koji Ogawa, Naoki Kawagishi, Akihisa Nakamura, Takashi Kitagataya, Kenichi Morikawa, Ren Yamada, Yoshimasa Tokuchi, Akinori Kubo, Machiko Umemura, Masato Nakai, Taku Shigesawa, Naoya Sakamoto
Publikováno v:
Journal of Gastroenterology. 55:1150-1161
Decompensated liver cirrhosis patients with refractory ascites or pleural effusion have a poor prognosis. Tolvaptan has been used for treating water retention associated with cirrhosis. However, despite the short-term response, water retention recurr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c8aa62105bf8857dbdf281fe5537bc0
https://doi.org/10.1007/s00535-020-01721-8
https://doi.org/10.1007/s00535-020-01721-8
Autor:
Takashi Kitagataya, Ren Yamada, Koji Yamamoto, Goki Suda, Masatsugu Ohara, Akihisa Nakamura, Machiko Umemura, Masaya Sugiyama, Kenichi Morikawa, Kazuharu Suzuki, Masato Nakai, Koji Ogawa, Naoki Kawagishi, Osamu Maehara, Naoya Sakamoto, Mitsuteru Natsuizaka, Masashi Mizokami, Takuya Sho, Hiroshi Takeda, Shunsuke Ohnishi, Megumi Kimura, Tomoe Shimazaki, Taku Shigesawa
Publikováno v:
Carcinogenesis. 42:58-69
In hepatocellular carcinoma (HCC), a subset of cells defined by high CD44 and CD133 expression has been reported to possess cancer stem-like cell (CSC) characteristics and to be associated with a poor prognosis. Since the approval of the multikinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5405705ef4f4d92753b49275146365e5
https://doi.org/10.1093/carcin/bgaa049
https://doi.org/10.1093/carcin/bgaa049
Autor:
Satoshi Takeuchi, Osamu Maehara, Akihiro Homma, Shunsuke Ohnishi, Naoya Sakamoto, Mitsuteru Natsuizaka, Akihisa Nakamura, Ren Yamada, Takashi Kitagataya, Megumi Kimura, Yoshito Komatsu, Koji Yamamoto, Kazunori Nagashima, Takehiko Katsurada, Goki Suda, Takashige Abe, Jun Sakakibara-Konishi, Masatsugu Ohara, Takanori Teshima, Machiko Umemura, Hiroo Hata, Masato Nakai, Kenichi Morikawa, Koji Ogawa, Naoki Kawagishi, Takuya Sho, Kazuharu Suzuki, Taku Shigesawa
Publikováno v:
Journal of Gastroenterology and Hepatology. 35:1782-1788
Background and Aim Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12e8451ace7798c907908b9d5555c2e7
https://doi.org/10.1111/jgh.15041
https://doi.org/10.1111/jgh.15041
Autor:
Masato Nakai, Akihisa Nakamura, Tomoe Shimazaki, Machiko Umemura, Mutsumi Nishida, Masatsugu Ohara, Megumi Kimura, Kenichi Morikawa, Ren Yamada, Kazuharu Suzuki, Naoya Sakamoto, Mitsuteru Natsuizaka, Koji Ogawa, Naoki Kawagishi, Taku Shigesawa, Takashi Kitagataya, Goki Suda, Takuya Sho, Osamu Maehara, Yusuke Kudo
Publikováno v:
Hepatology Research. 50:671-681
Aim Factors associated with improvement of liver fibrosis after successful hepatitis C virus (HCV) eradication by interferon (IFN)-free direct-acting antiviral agents (DAAs) have been not clarified well. Angiopoietin-2 (Ang2) is reported to be associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::def019f4eb03336249c586408e6b506b
https://doi.org/10.1111/hepr.13490
https://doi.org/10.1111/hepr.13490